NovoCure Ltd [NVCR] stock is trading at $27.96, up 5.11%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The NVCR shares have gain 39.52% over the last week, with a monthly amount glided 54.48%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
NovoCure Ltd [NASDAQ: NVCR] stock has seen the most recent analyst activity on December 02, 2024, when Evercore ISI upgraded its rating to a Outperform and also boosted its price target to $30 from $18. Previously, H.C. Wainwright upgraded its rating to Buy on October 16, 2024, and elevated its price target to $30. H.C. Wainwright downgraded its rating to a Neutral and decreased its price target to $25 on August 28, 2023. Piper Sandler upgraded its rating to a Overweight but $45 remained the price target by the analyst firm on August 08, 2023. SVB Securities started tracking with a Outperform rating for this stock on August 04, 2023, and assigned it a price target of $51. In a note dated July 31, 2023, Evercore ISI upgraded an In-line rating on this stock but restated the target price of $33.
NovoCure Ltd [NVCR] stock has fluctuated between $11.66 and $32.60 over the past year. Currently, Wall Street analysts expect the stock to reach $30 within the next 12 months. NovoCure Ltd [NASDAQ: NVCR] shares were valued at $27.96 at the most recent close of the market. An investor can expect a potential return of 7.3% based on the average NVCR price forecast.
Analyzing the NVCR fundamentals
NovoCure Ltd [NASDAQ:NVCR] reported sales of 577.74M for the trailing twelve months, which represents a growth of 21.81%. Gross Profit Margin for this corporation currently stands at 0.76% with Operating Profit Margin at -0.28%, Pretax Profit Margin comes in at -0.2%, and Net Profit Margin reading is -0.26%. To continue investigating profitability, this company’s Return on Assets is posted at -0.12, Equity is -0.41 and Total Capital is -0.33. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.81.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 26.81 points at the first support level, and at 25.67 for the second support level. However, for the 1st resistance point, the stock is sitting at 28.74, and for the 2nd resistance point, it is at 29.53.
Ratios To Look Out For
For context, NovoCure Ltd’s Current Ratio is 1.49. In addition, the Quick Ratio stands at 1.44 and the Cash Ratio stands at 0.25. Considering the valuation of this stock, the price to sales ratio is 5.50, the price to book ratio is 8.38.
Transactions by insiders
Recent insider trading involved Paravasthu Mukund, Chief Operating Officer, that happened on Nov 02 ’24 when 44.0 shares were sold. Chief Human Resources Officer, Puri Michal Nath completed a deal on Oct 31 ’24 to sell 810.0 shares. Meanwhile, EVP, Pres., Novocure Oncology Leonard Frank X sold 598.0 shares on Nov 01 ’24.
